Category: News

A Review from the team just published in J Mater Chem B!!! Inorganic polymerization: an attractive route to biocompatible hybrid hydrogels

Congratulations for the first paper of Titouan!

J. Mater. Chem. B, 2018,6, 3434-3448,  doi 10.1039/C8TB00456K

T

Titouan is the first author of a really nice, well illustrated and comprehensive review about hybrid hydrogels, (i.e. defined by the coexistence of organic and inorganic moieties in water). Inorganic polymerization, i.e. the sol–gel process, is one of the main techniques leading to hybrid hydrogels. In addition, the mild reaction conditions make this process very promising for the preparation of water-containing materials and their bio-applications.

Have a look at J Mater Chem B !

J. Mater. Chem. B, 2018,6, 3434-3448,  doi 10.1039/C8TB00456K

T

Our teams recorded great results at the Montpellier marathon 2018!

Mens sana in corpore sano !

Two marathon relay teams from our group registered great times at this year edition of the Montpellier Marathon. Our senior team finished in just under 3 hours at the amazing 10th place out of 380 teams. Our youth team recorded a great result for their first participation and finished 88th for about 3h 50min. Congratulations to both teams for the participation and the achievments !

Macrilen (JMV 1843) – a drug developed by our group just got approved by FDA !!!

macrilen

Macrilen, a revolution in the growth hormone  dose-titration !

MacrilenTM (JMV 1843), conceptualized and synthesized in IBMM, is the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency. It is a novel, orally active small molecule that mimics the ghrelin hormone and stimulates the secretion of growth hormone by activation of the ghrelin receptor. A single ingestion of this compound, followed by titration of growth hormone in the blood, allows the evaluation of growth hormone deficiency. It has been approved by the FDA for the diagnosis of growth hormone deficiency in adults and will be commercialized by Æterna-Zentaris in USA and Canada in 2018. It should find other applications such as treatment of cachexia and we are waiting its approval for the diagnosis in Europe.

New publication on importance of peptide orientation on titanium surface

Congrats to Gilles and Nicolas for their new paper!

Our team demonstrates for the first time that the controlled orientation of silylated hybrid-temporins on titanium surfaces could improve antibacterial activity of the material. In collaboration with Dr Vincent Humblot (UMR CNRS 7197, Paris) and Pr Ahmad Mehdi (Institute Charles Gerhardt, Montpellier), we designed 5 analogues of the antimicrobial peptide temporin SHa and studied the impact of the site-specific and orientation of the peptides on the antibacterial activity of the grafted titanium device. This work is published in J. Mater. Chem. B (DOI: 10.1039/c8tb00051d).